Elucid Bioimaging Inc.

Based in Massachusetts, US, and founded in 2013, Elucid operates as a medical technology company providing software based on machine learning and historical data. The company was founded by Marc Manley (CEO) and Andrew Buckler (President). In June 2022, the company raised a 27 million USD series B funding round with participation from a new investor Biovision Ventures, MedTex Ventures, and IAG Capital. Elucid uses machine learning and historical data to diagnose and treat cardiovascular disease accurately.

The company’s product is ElucidVivo with PlaqueIQTM Technology includes image analysis software that employs CT angiography and patented computer algorithms based on histological data which is to find the actual position of arterial plaque to create personalized patient care. The software works with all CTA Scanners using standard acquisition protocols and sensitive patient data is protected. The software uses an electronic medical recorder (EMR) and picture archiving and communication system (PACS) for timely clinical decision-making. Elucid also provides a software named ElucidVivo™ Clinical Research for clinical research and studies.

The company plans to launch a product called ElucidViviTM FFRCT + PlaqueIQ which is a combination of plaque analysis, and Fractional Flow Reserve (FFR) for a more direct measure of stress while giving information about plaque risk. The company plans to use the June 2022 funds to accelerate growth and development.